N Engl J Med 2011 Dec 29
A phase 3 trial of bevacizumab in ovarian cancer.
Related Questions
With the recent publication of GOG252 - does this change your management for patients with ovarian cancer who undergo primary surgery who have an opti...
New answer by at University of California Irvine Medical Center (May 16, 2019)
If they are wild type (i.e., no germline BRCA1/2 mutation) I would then test the tumor for somatic BRCA1/2. If that's negative and they have no contraindication to anti-angi...
New answer by Medical Oncologist at University of Pittsburgh Magee Womens Hospital (January 15, 2019)
The answer to this question is definitively NO.Two large, definitive studies (ICON-7 and GOG218 – including over 3400 patient combined) evaluated the impact of adjuvant ...
How (if at all) does this change your counseling and willingness to add bevacizumab to a regimen?
New answer by at Columbia University Medical Center (October 6, 2020)
This is really a two parts question. The first question would be, do you offer bevacizumab to all your ovarian cancer patients and the second question would be what patients w...
Patient is currently cycle 5/6 of carboplatin/taxol and tolerating well, has received no bevacizumab.
New answer by at UCLA David Geffen School of Medicine/UCLA Medical Center (November 26, 2020)
For an optimally cytoreduced patient with Stage III ovarian carcinosarcoma, I would not add bevacizumab unless the patient was "optimal" at interval surgery and had neoadjuvan...
New answer by Medical Oncologist at Harvard Medical School (July 15, 2019)
In GOG-252, the control arm (arm 1) was the dose-dense Japanese GOG (JGOG) regimen, compared to two IP-based arms (arm 2, IP carboplatin, and arm 3, IP cisplatin). As st...
New answer by at Cooper Medical School of Rowan University (November 1, 2024)
I use 15 mg/kg (please note that bevacizumab dosing is by weight, not per m2) as per GOG-0218. The toxicity is reasonable and the PFS was 4 mo compared to 2 mo for ICON7. Admi...